IL236785B - Anti-pcsk9 antibodies with ph-dependent binding characteristics - Google Patents

Anti-pcsk9 antibodies with ph-dependent binding characteristics

Info

Publication number
IL236785B
IL236785B IL236785A IL23678515A IL236785B IL 236785 B IL236785 B IL 236785B IL 236785 A IL236785 A IL 236785A IL 23678515 A IL23678515 A IL 23678515A IL 236785 B IL236785 B IL 236785B
Authority
IL
Israel
Prior art keywords
binding characteristics
dependent binding
pcsk9 antibodies
pcsk9
antibodies
Prior art date
Application number
IL236785A
Other languages
English (en)
Hebrew (he)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL236785B publication Critical patent/IL236785B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL236785A 2012-08-13 2015-01-19 Anti-pcsk9 antibodies with ph-dependent binding characteristics IL236785B (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261682349P 2012-08-13 2012-08-13
US201261703342P 2012-09-20 2012-09-20
US201261734398P 2012-12-07 2012-12-07
US201361761383P 2013-02-06 2013-02-06
US201361828258P 2013-05-29 2013-05-29
PCT/US2013/054456 WO2014028354A1 (en) 2012-08-13 2013-08-12 Anti-pcsk9 antibodies with ph-dependent binding characteristics

Publications (1)

Publication Number Publication Date
IL236785B true IL236785B (en) 2018-10-31

Family

ID=50066319

Family Applications (1)

Application Number Title Priority Date Filing Date
IL236785A IL236785B (en) 2012-08-13 2015-01-19 Anti-pcsk9 antibodies with ph-dependent binding characteristics

Country Status (15)

Country Link
US (1) US9540449B2 (enExample)
EP (1) EP2882778B1 (enExample)
JP (1) JP6309521B2 (enExample)
KR (1) KR20150041662A (enExample)
CN (1) CN104540852B (enExample)
AR (1) AR092098A1 (enExample)
AU (1) AU2013302925B2 (enExample)
CA (1) CA2881679C (enExample)
EA (1) EA028244B1 (enExample)
IL (1) IL236785B (enExample)
MX (1) MX363213B (enExample)
NZ (1) NZ704771A (enExample)
TW (1) TWI596115B (enExample)
UY (1) UY34975A (enExample)
WO (1) WO2014028354A1 (enExample)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
WO2007114325A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 二重特異性抗体を精製するための抗体改変方法
IN2014DN10515A (enExample) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
DK3059246T3 (en) 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modified constant region of an antibody
MX336725B (es) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
TWI700293B (zh) 2008-04-11 2020-08-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗體
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP6013915B2 (ja) 2010-11-17 2016-10-25 中外製薬株式会社 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子
KR102568454B1 (ko) 2010-11-30 2023-08-18 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
BR112013018740A2 (pt) 2011-01-28 2019-01-08 Sanofi Sa anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos
EP3604330A1 (en) 2011-02-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc antibody
US9890218B2 (en) 2011-06-30 2018-02-13 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
CN103930444B (zh) 2011-09-16 2020-08-04 瑞泽恩制药公司 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
BR112014013081A2 (pt) 2011-11-30 2020-10-20 Chugai Seiyaku Kabushiki Kaisha veículo contendo fármaco em célula para formação de um complexo imune
JP6226752B2 (ja) 2012-02-09 2017-11-08 中外製薬株式会社 抗体のＦｃ領域改変体
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
TWI596115B (zh) 2012-08-13 2017-08-21 再生元醫藥公司 具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
EP3597747B1 (en) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
CN113788897A (zh) * 2013-03-15 2021-12-14 拜尔健康护理有限责任公司 改善药代动力学的具有跨pH范围差异结合的抗TFPI抗体变体
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TW202021614A (zh) 2013-06-07 2020-06-16 法商賽諾菲生物技術公司 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
SG10201803449VA (en) 2013-09-27 2018-05-30 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI656133B (zh) 2014-12-19 2019-04-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
KR101838645B1 (ko) * 2014-12-19 2018-03-14 추가이 세이야쿠 가부시키가이샤 항-c5 항체 및 그의 사용 방법
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
EP3263132B1 (en) 2015-02-27 2023-12-06 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
WO2016156468A1 (en) * 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
CN107454905B (zh) 2015-03-31 2023-04-28 索里索制药公司 多肽
CN107427577A (zh) 2015-03-31 2017-12-01 韦斯夸尔德有限公司 具有蛋白酶可切割接头的肽构建体
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
EP3549606A1 (en) * 2015-05-28 2019-10-09 Bio-rad Laboratories, Inc. Affinity ligands and methods relating thereto
CN106084058B (zh) * 2015-07-15 2019-08-27 北京天广实生物技术股份有限公司 抗人pcsk9单克隆抗体
TWI899515B (zh) 2015-08-04 2025-10-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
CN106589127A (zh) * 2015-10-16 2017-04-26 钜川生物医药 一种pcsk9抗体及其制备方法和应用
AR107078A1 (es) * 2015-12-18 2018-03-21 Chugai Pharmaceutical Co Ltd Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
KR102467124B1 (ko) * 2015-12-18 2022-11-15 추가이 세이야쿠 가부시키가이샤 항-c5 항체 및 사용 방법
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CA3004288C (en) 2015-12-28 2025-05-27 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PROMOTING THE CLEARANCE EFFICIENCY OF A POLYPEPTIDE CONTAINING THE FC REGION
EP3401336A4 (en) * 2016-01-05 2020-01-22 Jiangsu Hengrui Medicine Co., Ltd. ANTI-PCSK9 ANTIBODIES, ASSOCIATED ANTIGEN BINDING FRAGMENT, AND ASSOCIATED MEDICAL APPLICATION
TW202214700A (zh) 2016-03-14 2022-04-16 日商中外製藥股份有限公司 用於癌之治療的細胞傷害誘導治療劑
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN105801701B (zh) * 2016-03-31 2019-03-29 河北仁博科技有限公司 一种pcsk9抗体的重链和轻链可变区及其应用
AU2017255077B2 (en) 2016-04-28 2024-05-16 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
PE20240825A1 (es) * 2016-06-17 2024-04-18 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y metodos de uso
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
PT3596125T (pt) 2017-03-16 2025-11-27 Medimmune Ltd Anticorpos anti-par2 e suas utilizações
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
GB201707484D0 (en) * 2017-05-10 2017-06-21 Argenx Bvba Method of preparing ph-dependent antibodies
CN114075269A (zh) 2017-07-06 2022-02-22 菲仕兰坎皮纳荷兰私人有限公司 用于制备糖蛋白的细胞培养工艺
BR112020008393A2 (pt) 2017-11-01 2020-11-03 Chugai Seiyaku Kabushiki Kaisha variante e isoforma de anticorpos com atividade biológica reduzida
EP3710589A4 (en) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHOD OF USING
CN111479618B (zh) 2017-12-22 2022-08-02 瑞泽恩制药公司 用于表征药物产品杂质的系统和方法
KR20200115485A (ko) 2018-01-31 2020-10-07 리제너론 파마슈티칼스 인코포레이티드 약물 생성물 불순물을 특성화하기 위한 시스템 및 방법
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
US12460270B2 (en) 2018-02-28 2025-11-04 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
BR112020015291B1 (pt) 2018-03-19 2023-09-26 Regeneron Pharmaceuticals, Inc Tampão de amostra de eletroforese aquoso, método para identificar contaminantes ou impurezas em uma amostra de fármaco proteico, e, kit
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
KR102697702B1 (ko) 2018-08-10 2024-08-22 추가이 세이야쿠 가부시키가이샤 항cd137 항원 결합 분자 및 그의 사용
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
KR20210053816A (ko) 2018-08-30 2021-05-12 리제너론 파마슈티칼스 인코포레이티드 단백질 복합체를 특성화하기 위한 방법
NZ775959A (en) * 2018-10-31 2022-08-26 Bioatla Inc Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
IL284471B2 (en) 2019-01-16 2025-01-01 Regeneron Pharma Methods for identifying free thiols in proteins
RS66416B1 (sr) 2019-01-18 2025-02-28 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluorometoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i metode njegove primene
JP7720785B2 (ja) 2019-04-18 2025-08-08 ブリストル－マイヤーズ スクイブ カンパニー 低ｐＨで結合するために特異性が増強されたイピリムマブバリアント
EP3969908A1 (en) 2019-05-13 2022-03-23 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
BR112021021689A2 (pt) 2019-05-15 2022-03-22 Chugai Pharmaceutical Co Ltd Molécula de ligação a antígeno, composição farmacêutica, e método
CA3139943A1 (en) 2019-05-17 2020-11-26 Regeneron Pharmaceuticals, Inc. Genome-based methods for reducing cardiovascular risk
AU2020296979A1 (en) 2019-06-21 2022-02-24 Sorriso Pharmaceuticals, Inc. Polypeptides
MX2021015761A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Polipeptidos.
MX2021015762A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Composiciones.
EP4017878A4 (en) * 2019-08-19 2023-09-13 The Rockefeller University Engineering ph-dependent antigen binding activity into anti-hiv antibodies with improved pharmacokinetics
CN110669778A (zh) * 2019-09-19 2020-01-10 上海药明生物技术有限公司 一种对抗体pH依赖结合活性的快速改造及筛选方法
EP4653865A3 (en) 2019-09-24 2026-02-18 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
WO2021063352A1 (zh) * 2019-09-30 2021-04-08 和铂医药(上海)有限责任公司 一种抗pd-l1抗原结合蛋白及其应用
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
MX2022006236A (es) 2019-11-25 2022-06-22 Regeneron Pharma Formulaciones de liberacion sostenida con emulsiones no acuosas.
KR102544013B1 (ko) 2020-01-21 2023-06-19 리제너론 파마슈티칼스 인코포레이티드 당질화된 단백질의 전기영동을 위한 탈당질화 방법
US20230235074A1 (en) * 2020-06-19 2023-07-27 Board Of Regents, The University Of Texas System Anti-bst2 antibodies targeting bst2 long isoform
CA3192999A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
EP4251128A1 (en) 2020-11-25 2023-10-04 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
WO2022133135A1 (en) 2020-12-17 2022-06-23 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
CN116761880A (zh) 2021-01-20 2023-09-15 瑞泽恩制药公司 改进细胞培养物中的蛋白质滴度的方法
WO2022177870A1 (en) * 2021-02-17 2022-08-25 The Board Of Regents Of The University Of Texas System Multimeric sars-cov-2 binding molecules and uses thereof
CA3207883A1 (en) 2021-03-03 2022-09-09 Xiaobin Xu Systems and methods for quantifying and modifying protein viscosity
US20220309215A1 (en) 2021-03-26 2022-09-29 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
AU2022286340A1 (en) 2021-06-01 2024-01-04 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
WO2023039457A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins
AU2022348521A1 (en) 2021-09-20 2024-04-04 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
KR20240090312A (ko) 2021-10-07 2024-06-21 리제너론 파아마슈티컬스, 인크. Ph 미터 보정 및 교정
CN118076894A (zh) 2021-10-07 2024-05-24 里珍纳龙药品有限公司 pH建模和控制的系统及方法
KR20240097864A (ko) 2021-10-26 2024-06-27 리제너론 파마슈티칼스 인코포레이티드 상이한 온도에서 실험실 용수를 생성하고 실험실 용수를 분배하는 시스템 및 방법
CA3245647A1 (en) 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. METHODS AND SYSTEMS FOR ANALYZING POLYPEPTIDE VARIANTS
TW202435942A (zh) 2022-12-16 2024-09-16 美商里珍納龍藥品有限公司 評估層析管柱完整性的方法及系統
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
TW202445126A (zh) 2023-01-25 2024-11-16 美商再生元醫藥公司 基於質譜法之體內共表現抗體之表徵
TW202445138A (zh) 2023-02-01 2024-11-16 美商再生元醫藥公司 用於生物巨分子分析之具質譜法的不對稱流場流分離
WO2024178213A2 (en) 2023-02-22 2024-08-29 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
WO2024218743A1 (en) 2023-04-21 2024-10-24 Glycoera Ag Multi-functional molecules comprising glycans and uses thereof
TW202508625A (zh) 2023-05-01 2025-03-01 美商再生元醫藥公司 使用苯酚或苯甲醇之多劑量抗體藥物產品
US20250086164A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2025064403A2 (en) 2023-09-18 2025-03-27 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
US20250109905A1 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
US20250129117A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
US20250145662A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
WO2026025028A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Methods of making ultra-high concentrated protein formulations using lyophilization

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070224663A1 (en) 1997-03-07 2007-09-27 Human Genome Sciences, Inc. Human Secreted Proteins
EP1514933A1 (en) 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
US7129338B1 (en) 1999-07-08 2006-10-31 Research Association For Biotechnology Secretory protein or membrane protein
US7029895B2 (en) 1999-09-27 2006-04-18 Millennium Pharmaceuticals, Inc. 27411, a novel human PGP synthase
CA2399727A1 (en) 2000-02-07 2001-08-09 Millennium Pharmaceuticals, Inc. Narc-1, subtilase-like homologs
WO2002020767A2 (en) 2000-09-08 2002-03-14 Massachusetts Institute Of Technology G-csf analog compositions and methods
EP1471152A1 (en) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
US20060057639A1 (en) 2004-06-16 2006-03-16 Pitt Geoffrey S CaMKII/calcium channel phosphorylation-related compositions and methods
US20060147945A1 (en) 2005-01-06 2006-07-06 Edmonds Brian T Novel secreted proteins and their uses
AU2007227251A1 (en) 2006-03-20 2007-09-27 Amgen Fremont, Inc. Antibodies directed to angiopoietin-like protein 4 and uses thereof
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2083861A4 (en) 2006-11-07 2010-11-24 Merck Sharp & Dohme ANTAGONISTS OF PCSK9
WO2008057457A2 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
CA2667989A1 (en) 2006-11-07 2008-11-06 Merck & Co., Inc. Antagonists of pcsk9
WO2008057458A2 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
CN101855241B (zh) 2006-12-08 2013-11-06 莱克康制药公司 针对angptl3的单克隆抗体
WO2008125623A2 (en) 2007-04-13 2008-10-23 Novartis Ag Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
SG2013014352A (en) 2007-10-26 2014-09-26 Merck Sharp & Dohme Anti-pcsk9 and methods for treating lipid and cholesterol disorders
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
TWI700293B (zh) 2008-04-11 2020-08-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗體
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8357371B2 (en) * 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
WO2011037791A1 (en) 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Antagonists of pcsk9
WO2011039578A1 (en) 2009-10-02 2011-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of spla2 activity and lp(a) cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
WO2011053759A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax1 and ax189 pcsk9 antagonists and variants
EP2493507A4 (en) 2009-10-30 2013-11-20 Merck Sharp & Dohme AX213 AND AX132 PCSK9 ANTAGONISTS AND VARIANTS THEREOF
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
TW201206466A (en) * 2010-03-11 2012-02-16 Rinat Neuroscience Corp Antibodies with pH dependent antigen binding
EP2545079A2 (en) 2010-03-11 2013-01-16 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
CA2820953A1 (en) 2010-12-22 2012-06-28 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
BR112013018740A2 (pt) 2011-01-28 2019-01-08 Sanofi Sa anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos
CN103562227B (zh) 2011-02-11 2016-12-21 诺瓦提斯公司 Pcsk9拮抗剂
AR088782A1 (es) 2011-04-29 2014-07-10 Sanofi Sa Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
PT2825037T (pt) * 2012-03-16 2019-08-07 Regeneron Pharma Animais não humanos que expressam sequências de imunoglobulinas sensíveis ao ph
RU2014141536A (ru) * 2012-03-16 2016-05-10 Регенерон Фармасьютикалз, Инк. Мыши, которые продуцируют антигенсвязывающие белки с зависимыми от величины ph характеристиками связывания
TWI596115B (zh) 2012-08-13 2017-08-21 再生元醫藥公司 具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體

Also Published As

Publication number Publication date
JP6309521B2 (ja) 2018-04-11
NZ704771A (en) 2018-02-23
US20140044730A1 (en) 2014-02-13
AU2013302925B2 (en) 2018-07-05
TW201420605A (zh) 2014-06-01
CN104540852B (zh) 2018-10-02
TWI596115B (zh) 2017-08-21
EP2882778A1 (en) 2015-06-17
CN104540852A (zh) 2015-04-22
EP2882778B1 (en) 2018-04-11
JP2015526440A (ja) 2015-09-10
AR092098A1 (es) 2015-03-25
HK1211603A1 (en) 2016-05-27
MX363213B (es) 2019-03-15
CA2881679A1 (en) 2014-02-20
WO2014028354A1 (en) 2014-02-20
CA2881679C (en) 2021-01-26
AU2013302925A1 (en) 2015-02-26
MX2015001907A (es) 2015-06-05
EA028244B1 (ru) 2017-10-31
EA201590370A1 (ru) 2015-05-29
KR20150041662A (ko) 2015-04-16
US9540449B2 (en) 2017-01-10
UY34975A (es) 2014-03-31

Similar Documents

Publication Publication Date Title
IL236785B (en) Anti-pcsk9 antibodies with ph-dependent binding characteristics
IL264558A (en) Anti–il–23p19 antibodies
SG11201405164QA (en) Mice that produce antigen-binding proteins with ph-dependent binding characteristics
ZA201407509B (en) Anti-fcrn antibodies
ZA201504478B (en) Immunotherapy with binding agents
ZA201407897B (en) Protease-regulated antibodies
ZA201409358B (en) Anti-siglec- 15 antibodies
ZA201407316B (en) Anti-fgfr2 antibody
EP2782601A4 (en) IL-1 BINDING PROTEINS
SG10201709290XA (en) Anti-H7cr Antibodies
PL2928935T3 (pl) Środki wiążące
ZA201407079B (en) Cdr-modified anti-siglec-15 antibody
GB201220242D0 (en) Antibody
EP2804876A4 (en) NEW ANTIBODIES
GB201418608D0 (en) Peridinin-chlorophyll binding proteins
EP2811018A4 (en) ANTI-BODY ANTI-sAPPß
IL235188A0 (en) Antibodies against c-pdgf
GB201209584D0 (en) Modified antibodies
GB201216296D0 (en) Reversibly inhibited antibodies
GB201216749D0 (en) Antigen combinations
GB201200568D0 (en) Antigen combinations

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed